Last reviewed · How we verify

zidovudine + lamivudine + efavirenz — Competitive Intelligence Brief

zidovudine + lamivudine + efavirenz (zidovudine + lamivudine + efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

zidovudine + lamivudine + efavirenz (zidovudine + lamivudine + efavirenz) — Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
zidovudine + lamivudine + efavirenz TARGET zidovudine + lamivudine + efavirenz Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase
Atazanavir + Ritonavir + 2 NRTIs Atazanavir + Ritonavir + 2 NRTIs Bristol-Myers Squibb marketed Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors) HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4)
Twice-daily ABC+3TC Twice-daily ABC+3TC Medical Research Council marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
Tenofovir (TDF) Tenofovir (TDF) French National Agency for Research on AIDS and Viral Hepatitis marketed Nucleotide reverse transcriptase inhibitor (NtRTI) HIV reverse transcriptase; Hepatitis B polymerase
Regimen:TDF+3TC+EFV Regimen:TDF+3TC+EFV National Center for AIDS/STD Control and Prevention, China CDC marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase
AZT+3TC+ABV (Trizivir) AZT+3TC+ABV (Trizivir) Fundacion SEIMC-GESIDA marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
Symtuza® (TAF/FTC/DRV/c) Symtuza® (TAF/FTC/DRV/c) Fundacion SEIMC-GESIDA marketed Antiretroviral combination (NRTI/INSTI class with protease inhibitor) HIV reverse transcriptase, HIV protease, CYP3A4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

  1. GlaxoSmithKline · 2 drugs in this class
  2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
  3. Hospital Clinic of Barcelona · 1 drug in this class
  4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
  5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
  6. Peking Union Medical College Hospital · 1 drug in this class
  7. Sheba Medical Center · 1 drug in this class
  8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
  9. University of KwaZulu · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). zidovudine + lamivudine + efavirenz — Competitive Intelligence Brief. https://druglandscape.com/ci/zidovudine-lamivudine-efavirenz. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: